NEW YORK (GenomeWeb) – Agendia said on Thursday that its MammaPrint 70-gene signature breast cancer recurrence risk test is now covered by Blue Shield of California.

According to the company, the payor has updated its medical policy to state that "the use of MammaPrint is considered medically necessary in women who are diagnosed with primary invasive breast cancer."

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.